Summary
Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals, Inc., which focuses on the development of novel therapeutics to treat gut microbiome. Its pipeline product portfolio includes SYN-010 and SYN-004. The company’s SYN-010, a drug candidate which is intended to treat rritable bowel syndrome with constipation (IBS-C) and SYN-004 is used to prevent C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Synthetic Biologics’s develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company works in collaboration with various academic and pharmaceutical companies, to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.
Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 11
Partnerships 13
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 13
Intrexon Enters into Partnership with Synthetic Biologics 14
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 15
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 17
Adeona Pharma Enters Into Co-Development Agreement With Meda 19
Licensing Agreements 21
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 21
Equity Offering 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 23
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 25
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units 27
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 29
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 31
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million 33
Adeona Pharma Completes Registered Direct Offering For US$4 Million 35
Adeona Pharma Completes Private Placement Of US$1 Million 37
Acquisition 39
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 39
Synthetic Biologics Inc - Key Competitors 40
Key Employees 41
Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 11
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 13
Intrexon Enters into Partnership with Synthetic Biologics 14
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 15
Adeona Pharma Enters Into Co-Development Agreement With Intrexon 17
Adeona Pharma Enters Into Co-Development Agreement With Meda 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 21
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 23
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 25
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units 27
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million 29
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million 31
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million 33
Adeona Pharma Completes Registered Direct Offering For US$4 Million 35
Adeona Pharma Completes Private Placement Of US$1 Million 37
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 39
Synthetic Biologics Inc, Key Competitors 40
Synthetic Biologics Inc, Key Employees 41
Synthetic Biologics Inc, Other Locations 42
Synthetic Biologics Inc, Subsidiaries 42
List of Figures
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
